Amgen's Evolocumab Meets Primary Endpoint

Amgen (NASDAQ: AMGN  ) has gotten one important step closer to bringing its "bad" cholesterol-reducing treatment to market. The company announced that its evolocumab treatment met its primary endpoint in a Phase 3 TESLA trial, saying that the percent reduction of lipoprotein (the so-called "bad") cholesterol over time was "clinically meaningful and statistically significant."

In the company's words, evolocumab is "an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove [lipoprotein cholesterol] from the blood."

TESLA is a two-part Phase 2/3 trial whose initials stand for "Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities."

The market for bad cholesterol-reducing medications is a highly competitive one, with several prominent pharmaceutical companies pushing to bring such treatments to market.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2879035, ~/Articles/ArticleHandler.aspx, 12/20/2014 10:25:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement